| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.24 | 0.4 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.004 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.16 | 0.004 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.15 | 0.002 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.15 | 0.003 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.15 | 0.002 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.14 | 0.004 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.13 | 0.002 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.3 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |